The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Tkacheva O.N.

Moscow Regional Research Institute of Obstetrics and Gynecology, Moscow, Russia

Ostroumova O.D.

Kafedra fakul'tetskoĭ terapii i professional'nykh bolezneĭ Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta im. A.I. Evdokimova, Moskva

Krasnov G.S.

Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation

Isaev R.I.

Russian Clinical and Research Center of Gerontology of Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia

Kotovskaya Yu.V.

FGBOU VO RNIMU OSP «Russian gerontological scientific and clinical center» named after N.I. Pirogov, Moscow, Russia

Evidence database for deprescribing of antipsychotic drugs in elderly and senile patients

Authors:

Tkacheva O.N., Ostroumova O.D., Krasnov G.S., Isaev R.I., Kotovskaya Yu.V.

More about the authors

Read: 1538 times


To cite this article:

Tkacheva ON, Ostroumova OD, Krasnov GS, Isaev RI, Kotovskaya YuV. Evidence database for deprescribing of antipsychotic drugs in elderly and senile patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(5):162‑172. (In Russ.)
https://doi.org/10.17116/jnevro2019119051162

Recommended articles:
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
Prospects for treating Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):54-60
Treatment features of patients with vascular cognitive impairments. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):69-76
Novel prospects for early diagnosis of cognitive impairment using Eye-tracking technology. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):13-20
Cardiogenic deme­ntia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):43-49
Clinical mani­festation of apical hype­rtrophic cardiomyopathy by syncope in the elde­rly. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):237-243

References:

  1. Sychev DA. Polypragmazia in Clinical Practice: problem and resheniya. SPb.: COP «Professija»; 2016. (In Russ.)
  2. Martin-Pérez M, López de Andrés A, Hernández-Barrera V, Jiménez-García R, Jiménez-Trujillo I, Palacios-Ceña D, Carrasco-Garrido P, Prevalencia de polifarmacia en la población mayor de 65 años en España: análisis de las Encuestas Nacionales de Salud 2006 y 2011/12. Revista Española de Geriatría y Gerontología. 2017;52:1:2-8. https://doi.org/10.1016/j.regg.2016.07.006
  3. Jokanovic N, Tan EC, Dooley MJ, Kirkpatrick CM, Bell JS. Prevalence and factors associated with polypharmacy in long-term care facilities: a systematic review. J Am Med Dir Assoc. 2015;16(6):535:1-12. Epub 2015 Apr 11. https://doi.org/10.1016/j.jamda.2015.03.003
  4. Boeker EB, Ram K, Klopotowska JE, de Boer M, Creus MT, de Andrés AL, Sakuma M, Morimoto T, Boermeester MA, Dijkgraaf MGW. An individual patient data meta-analysis on factors associated with adverse drug events in surgical and non-surgical inpatients. Br J Clin Pharmacol. 2015;79(4):548-557. https://doi.org/10.1111/bcp.12504
  5. Jetha S. Polypharmacy, the Elderly, and Deprescribing. Consult Pharm. 2015;30(9):527-532. https://doi.org/10.4140/TCP.n.2015.527
  6. Depreskraibing ingibitorov protonnoi pompy u patsientov pozhilogo i starcheskogo vozrasta (proekt protokola, 03.12.18). http://rgnkc.ru/images/pdf_documets/Protokol_Depreskraibing
  7. Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, Dombrowski R, DuBeau CE, Pezzullo L, Epplin JJ, Flanagan N, Morden E, Hanlon J, Hollmann P, Laird R, Linnebur S, Sandhu S. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019. [Epub ahead of print] https://doi.org/10.1111/jgs.15767
  8. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2014;44(2):213-218. https://doi.org/10.1093/ageing/afu145
  9. Pazan F, Weiss C, Wehling M. The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People. Drugs Aging. 2018;35(1):61-71. https://doi.org/10.1007/s40266-017-0514-2
  10. Warlé-van Herwaarden MF, Kramers C, Sturkenboom MC, van den Bemt PM, De Smet PA; Dutch HARM-Wrestling Task Force. Targeting outpatient drug safety: recommendations of the Dutch HARM-Wrestling Task Force. Drug Saf. 2012;35(3):245-259. https://doi.org/10.2165/11596000-000000000-00000
  11. Metodicheskie rukovodstva «Farmakoterapiya u lic pozhilogo i starcheskogo vozrasta» (2018 g.). http://rgnkc.ru/images/projects_documents/Farmakoterapiya.pdf. Ssylka aktivna na 29.03.2018 (In Russ.)
  12. Garfinkel D. Poly-de-prescribing to treat polypharmacy: efficacy and safety. Ther Adv Drug Saf. 2018;9(1):25-43. https://doi.org/10.1177/2042098617736192
  13. Brulhart MI, Wermeille JP. Multidisciplinary medication review: evaluation of a pharmaceutical care model for nursing homes. Int J Clin Pharm. 2011;33:549-557. https://doi.org/10.1007/s11096-011-9506-1
  14. McIntyre C, McQuillan R, Bell C, Battistella M. Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy. Am J Kidney Dis. 2017;70(5):611-618. https://doi.org/10.1053/j.ajkd.2017.02.374
  15. Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, Rojas-Fernandez C, Walsh K, Welch V, Moayyedi P. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017;63(5):354-364.
  16. Farrell B, Black C, Thompson W, Rojas-Fernandez C, Lochnan H, Shamji S, Upshur R, Bouchard M, Welch V. Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline. Can Fam Physician. 2017;63(11):832-843.
  17. Bjerre LM, Farrell B, Hogel M, Graham L, Lemay G, McCarthy L, Raman-Wilms L, Rojas-Fernandez C, Sinha S, Thompson W, Welch V, Wiens A. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. Can Fam Physician. 2018;64(1):17-27.
  18. Pottie K, Thompson W, Davies S, Grenier J, Sadowski CA, Welch V, Holbrook A, Boyd C, Swenson R, Ma A, Farrell B. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339-351.
  19. Ostroumova OD, Goloborodova IV, Isaev RI, Pereverzev AP. Antipsychotic: Peculiarities of undesirable adverse reactions in elderly and senile age groups. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2019;119(2):105-117. (In Russ.). https://doi.org/10.17116/jnevro2019119021105
  20. Dmitrieva TB. Klinicheskaja psihiatrija. Per. s angl. M.: GEOTAR-Media; 1998. (In Russ.)
  21. Booker A, Jacob L, Bohlken J, Rapp M, Kostev K. Persistence with antipsychotics in dementia patients in Germany. Int J Clin Pharmacol Ther. 2016;54(11):835-840. https://doi.org/10.5414/cp202631
  22. Demenciya. VOZ. 2017 g. https://www.who.int/ru/news-room/fact-sheets/detail/dementia.Ssylka aktivna na 29.03.2018 (In Russ.)
  23. Bohlken J, Booker A, Kostev K. High Prevalence of Antipsychotic Medication Use in Dementia Patients in German Neuropsychiatric Practices. Fortschr Neurol Psychiatr. 2017;85(6):345-351. https://doi.org/10.1055/s-0043-104931
  24. Pringsheim T, Gardner DM. Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study. CMAJ Open. 2014;2(4):225-232. https://doi.org/10.9778/cmajo.20140009
  25. National Audit of Dementia care in general hospitals 2012—13 Second round audit report and update Royal College of Psychiatrists. 2013. https://www.hqip.org.uk/resource/national-audit-of-dementia-care-in-general-hospitals-2012-13-second-round-audit-report-and-update/
  26. Gallagher P, Curtin D, de Siún A, O’Shea E, Kennelly S, O’Neill D, Timmons S. Antipsychotic prescription amongst hospitalized patients with dementia. QJM. 2016;109(9):589-593. https://doi.org/10.1093/qjmed/hcw023
  27. Gardette V, Lapeyre-Mestre M, Coley N, Cantet C, Montastruc JL, Vellas B, Andrieu S. Antipsychotic use and mortality risk in community-dwelling Alzheimer’s disease patients: Evidence for a role of dementia severity. Curr Alzheimer Res. 2012;9(9):1106-1116. https://doi.org/10.2174/156720512803569037
  28. Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbæk G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: A population-based study. Am J Geriatr Psychiatry. 2014;22(4):321-331. https://doi.org/10.1016/j.jagp.2013.06.007
  29. Nielsen RE, Lolk A, Valentin JB, Andersen K. Cumulative dosages of antipsychotic drugs are associated with increased mortality rate in patients with Alzheimer’s dementia. Acta Psychiatr Scand. 2016;134(4):314-320. https://doi.org/10.1111/acps.12614
  30. Nielsen RE, Lolk A, Rodrigo-Domingo M, Valentin JB, Andersen K. Antipsychotic treatment effects on cardiovascular, cancer, infection, and intentional self-harm as cause of death in patients with Alzheimer’s dementia. Eur Psychiatry. 2017;42:14-23. https://doi.org/10.1016/j.eurpsy.2016.11.013
  31. Gisev N, Hartikainen S, Chen TF, Korhonen M, Bell JS. Effect of comorbidity on the risk of death associated with antipsychotic use among community-dwelling older adults. Int Psychogeriatr. 2012;24(7):1058-1064. https://doi.org/10.1017/s1041610212000117
  32. Ralph SJ, Espinet AJ. Increased All-Cause Mortality by Antipsychotic Drugs: Updated Review and Meta-Analysis in Dementia and General Mental Health Care. J Alzheimers Dis Rep. 2018;2(1):1-26. https://doi.org/10.3233/ADR-170042
  33. Koponen M, Taipale H, Lavikainen P, Tanskanen A, Tiihonen J, Tolppanen AM, Ahonen R, Hartikainen S. Risk of mortality associated with antipsychotic monotherapy and polypharmacy among community-dwelling persons with Alzheimer’s disease. J Alzheimers Dis. 2017;56(1):107-118. https://doi.org/10.3233/jad-160671
  34. Koponen M, Taipale H, Tanskanen A, Tolppanen AM, Tiihonen J, Ahonen R, Hartikainen S. Long-term use of antipsychotics among community-dwelling persons with Alzheimers disease: A nationwide register-based study. Eur Neuropsychopharmacol. 2015;25(10):1706-1713. https://doi.org/10.1016/j.euroneuro.2015.07.008
  35. Liperoti R, Sganga F, Landi F, Topinkova E, Denkinger MD, van der Roest HG, Foebel AD, Finne-Soveri H, Bernabei R, Onder G. Antipsychotic drug interactions and mortality among nursing home residents with cognitive impairment. J Clin Psychiatry. 2017;78(1):76-82. https://doi.org/10.4088/jcp.15m10303
  36. Pariente A, Fourrier-Reglat A, Ducruet T, Farrington P, Béland SG, Dartigues JF, Moore N, Moride Y. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med. 2012;172(8):648-653. https://doi.org/10.1001/archinternmed.2012.28
  37. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355(9209):1048-1052. https://doi.org/10.1016/S0140-6736(00)02035-3
  38. Kleijer BC, van Marum RJ, Egberts AC, Jansen PA, Knol W, Heerdink ER.. Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol. 2009;23(8):909-914. https://doi.org/10.1177/0269881108093583
  39. Nanasawa H, Sako A, Mitsutsuka T, Nonogaki K, Kondo T, Mishima S, Uju Y, Ito T, Enomoto T, Hayakawa T, Yanai H. Development of diabetes mellitus associated with quetiapine: A case series. Medicine (Baltimore). 2017;96(3):e5900. https://doi.org/10.1097/md.0000000000005900
  40. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ 3rd. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316(7):363-369. https://doi.org/10.1056/NEJM198702123160702
  41. Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int. 2006;17(6):807-816. https://doi.org/10.1007/s00198-005-0065-y
  42. Pouwels S, van Staa TP, Egberts AC, Leufkens HGM, Cooper C, de Vries F. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2009;20(9):1499-1506. https://doi.org/10.1007/s00198-008-0826-5
  43. Sorensen HJ, Jensen SO, Nielsen J. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis. Eur Neuropsychopharmacol. 2013;23(8):872-878. https://doi.org/10.1016/j.euroneuro.2013.04.002
  44. Van Leeuwen E, Petrovic M, van Driel ML, De Sutter AI, Vander Stichele R, Declercq T, Christiaens T. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018;3:CD007726. [Epub ahead of print]. https://doi.org/10.1002/14651858.cd007726.pub3
  45. Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AIM, van Driel ML, Christiaens T. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database of Systematic Reviews. 2013;3: CD007726. https://doi.org/10.1002/14651858.cd007726.pub2
  46. Ballard C, Thomas A, Fossey J, Lee L, Jacoby R, Lana MM, Bannister C, McShane R, Swann A, Juszczak E, O’Brien JT. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the Neuropsychiatric Inventory median cut-off is a predictor of clinical outcome. Journal of Clinical Psychiatry. 2004;65(1):114-119. https://doi.org/10.4088/jcp.v65n0120
  47. Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R, Jacoby R, Kossakowski K, Yu L-M, Juszczak E, and on behalf of the Investigators DART AD. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Medicine. 2008;5(4):e76. ISRCTN33368770. https://doi.org/10.1371/journal.pmed.0050076
  48. Bergh S, Selbæk G, Engedal K. Discontinuation in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial. BMJ. 2012 Mar 9;344:e1566. https://doi.org/10.1136/bmj.e1566
  49. Bridges-Parlet S, Knopman D, Steffes S. Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment controlled pilot study. Journal of Geriatric Psychiatry and Neurology. 1997;10(3):119-126. https://doi.org/10.1177/089198879701000306
  50. Cohen-Mansfield J, Lipson S, Werner P, Billig N, Taylor L, Woosley R. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home. Archives of Internal Medicine. 1999;159(15):1733-1740. https://doi.org/10.1001/archinte.159.15.1733
  51. Devanand D, Pelton G, Cunqueiro K, Sackeim HA, Marder K. A 6-month, randomized, double-blind, placebocontrolled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer’s disease. International Journal of Geriatric Psychiatry. 2011;26(9):937-943. https://doi.org/10.1002/gps.2630
  52. Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Levin B. Relapse risk after discontinuation of risperidone in Alzheimer’s disease. New England Journal of Medicine. 2012;367(16):1497-1507. https://doi.org/10.1056/nejmoa1114058
  53. Findlay DJ, Sharma J, McEwen J, Ballinger BR, MacLennan WJ, McHarg AM. Double-blind controlled withdrawal of thioridazinetreatments in elderly female inpatients with senile dementia. International Journal of Geriatric Psychiatry. 1989;4(2):115-120. https://doi.org/10.1002/gps.930040210
  54. Ruths S, Straand J, Nygaard H, Aarsland D. Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study — the Bergen District Nursing Home Study (BEDNURS). International Journal of Geriatric Psychiatry. 2008;23(9):889-895. https://doi.org/10.1002/gps.1998
  55. van Reekum R, Clarke D, Conn D, Herrmann N, Eryavec G, Cohen T, Ostrander L. A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. International Psychogeriatrics. 2002;14(2):197-210. https://doi.org/10.1017/s1041610202008396

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.